


Rejections under 35 U.S.C. § 103(a)

Claims 1-6 stand rejected under U.S.C. § 103(a) as being obvious over White et al. in view of Widdowson. The White et al. reference was published on April 24, 1998, approximately 5 months before the claimed priority date of the instant application, and therefore is not a statutory bar under 35 U.S.C. § 102(b). Applicant provides herewith a declaration under 37 C.F.R. § 1.131(a) wherein the inventor declares that the invention embodied by the pending claims was made prior to the publication of the White et al. reference. In particular, the embodiment of the instant invention set forth in Claims 1-3 was conceived and reduced to practice prior to April of 1998, and therefore antedates the White publication. Moreover, the embodiment of the instant invention set forth in Claims 4-6 was conceived and reduced to practice prior to April of 1998, and therefore antedates the White publication. Accordingly, the White et al. reference is not prior art against the instant invention.

Applicant asserts that the Widdowson reference by itself does not teach or suggest to one skilled in the art the instant invention. Applicant therefore respectfully requests withdrawal of the 35 U.S.C. § 103(a) rejection and allowance of the instant claims.

Attached hereto is a "**Version with Markings to Show Changes Made**" to the specification and claims by the current amendment. Applicant submits that this application is in condition for allowance and respectfully requests early and favorable notification to that effect. If it would expedite prosecution of this application, the Examiner is invited to confer with the Applicant's undersigned attorney.

Respectfully submitted,



William R. Majarian

Registration No. 41,173

GLAXOSMITHKLINE
Corporate Intellectual Property – UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5968
Facsimile (610) 270-5090

Version with Markings to Show Changes Made

In the Specification:

The newly added page to the specification is solely to incorporate the "Abstract" data. No changes have been made. Therefore, a marked up version is not required.

In the Claims:

2. (Amended) The method according to claim 1 wherein the compound is N-[2-Hydroxy-4-cyanophenyl]-N'-[2-bromophenyl] urea, or N-[☐]2-Hydroxy-4-nitrophenyl]-N'-(2-bromophenyl)urea or a pharmaceutically acceptable salt thereof.

4. (Amended) A method of inhibiting or blocking T-cell mediated chemotaxis in a patient in need thereof, which method comprises administering to said patient an effective amount of a compound which binds the CXCR2 receptor.

5. (Amended) The method of according to claim 4 wherein the compound is N-[☐]-Hydroxy-4-cyanophenyl]-N''-[2-bromophenyl] urea, or N-2[☐]-Hydroxy-4-nitrophenyl]-N'-(2-bromophenyl) urea or a pharmaceutically acceptable salt thereof.